Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

New Pivotal Data at EHA 2021 Reinforces Sutimlimab as a First-in-Class Investigational C1s Inhibitor with the Potential to be the First Approved Treatment for Hemolysis in People with Cold Agglutinin

drugsJune 21, 2021

Tag: Sutimlab , C1s Inhibitor , CAD

PharmaSources Customer Service